Immupharma Share Discussion Threads

[nobbygnome] 04/12/2020 10:17

The best you can hope for after this meeting is that the FDA might say they will consider it for compassionate approval. The file of data hasn't been submitted in its entirety so I can't see how they can possibly approve it now. And vaccine reviews notwithstanding, that sort of file would normally take at least 9 months to be reviewed.

So don't hold your breath for approval any time soon IMHO....

[csmwssk12hu] 04/12/2020 10:08

Well if it doesn’t get approved it could fall to 6-9p imho as initial reaction but I think it will get back to this level quite quickly, if it gets approved I think it will be over £2 instantly as it was 185 before it didn’t get approval last time and I’m sure it would have easily gone over £2 had it been approved, Lupus is nasty and if this can help even a quarter of people that’s better than nothing imho dyor

[alexios1201] 04/12/2020 09:15

MorningAnyone know the time of FDA minutes release?Thanks

[qazwsxedc69] 04/12/2020 08:50

Why complain? Surely a chance to top up? We all know the merest hint of good news and it's going stratospheric

[halfbutt] 04/12/2020 08:10

Re price.... you couldn't make this sxxt up... ffs 12p ???? Just before meeting !!!

[frrinvest] 02/12/2020 09:16

Anyway time will tell. If they get a conditional approval (small chance but still a chance) then the share price will move towards this target until the approval of phase 3. I am cautiously optimistic about phase 3 this time as Avion on board and will probably be managed properly with regard to the placebo effect.

Edit: In the last interview the CEO stated the decision for the conditional approval may be known within 2 weeks after 4th Dec. meeting. He did say FDA have a lot on their plate. But then again FDA did approve the Type A meeting reasonably quickly. So not long to wait.

[albert arthur] 02/12/2020 09:10

Video is one year old. With 66% if not more of the year being delayed by covid, the video may be old, but that does not change the target.

[albert arthur] 02/12/2020 09:09

That's was a link to the proactive page...This is the video 2 mins 27 inhttps://youtu.be/Ax7hTKajNnk

[frrinvest] 02/12/2020 09:09

Old interview fella. You are taking the P or out of time?

[adamfletcher1] 02/12/2020 09:06

It’s in this video:


hxxps://youtu.be/Ax7hTKajNnk

[frrinvest] 02/12/2020 08:56

Albert A - at 2:37 onwards there is NO mention of £1 target. Are you watching a different interview?

[tarny] 02/12/2020 07:07

Immupharma PLC IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
02/12/2020 7:00am
RNS Non-Regulatory

TIDMIMM

Immupharma PLC

02 December 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE(TM) DIGITAL 2021

11-15 January 2021

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma's Chief Operating Officer, will be presenting at the prestigious Biotech Showcase(TM) Digital 2021. The event will be virtually held between 11 and 15 January 2021.

As part of ImmuPharma's participation, an on-demand Company presentation has been provided in advance to the opening of the event. This will allow registered attendees to get access to presentation material prior to the start of the showcase on 11 January 2021.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

[albert arthur] 02/12/2020 07:05

CEO said it in the video 2 mins 37 secs in:https://www.proactiveinvestors.co.uk/companies/news/934781/immupharmas-partner-avion-set-to-meet-fda-in-december-to-discuss-phase-3-lupus-clinical-trial-934781.html

[mike1608] 02/12/2020 00:58

Where did you come up with £1 target😂

[albert arthur] 01/12/2020 22:44

This should have images. But sorry it does not, good old ADVFN:IIM FDA background:On September the 7th #IMM dropped a funding RNS for £6.5m at a placing price of 10p. They said this would fund them until 2023:IMM have a drug for Lupus and other autoimmune diseases. On 27 July IMM sent a submission to the FDA for their drug Lupuzor a drug for Lupus. Partnering with Avion Pharmaceuticals.The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, and is 1.6b today,according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.On the 10th of November the FDA responded agreeing to a type A meeting, note below, IMM have stated the are already producing Lupuzor for Phase 3 Trails: The meeting date is agreed for 4th December 2020.(This Friday).The CEO suggested in a video dated 25th of November under the partnership with Avion Pharmaceuticals the price of the share has now be revalued to a £1 target. See this video 24th November on proactive, 2 mins 38 seconds in:https://www.proactiveinvestors.co.uk/companies/news/934781/immupharmas-partner-avion-set-to-meet-fda-in-december-to-discuss-phase-3-lupus-clinical-trial-934781.htmlFor those who would like to understand a TYPE A meeting, see the below:And also this link:https://www.accessdata.fda.gov/cder/sb-navigate/topic3/topic3/da_01_03_0090.htmThere appears to be only one seller: Lanstead Capital Investors LP. Who bought 20% in April then sold off back to circa 10%. So they may hold the rest.This looks to have serious potential on a cap of just 24m and funding to 2023. FDA type A meeting in the pipeline and drug being made.

[albert arthur] 01/12/2020 11:43

For anyone does not understand "Type A" Meetings:https://www.accessdata.fda.gov/cder/sb-navigate/topic3/topic3/da_01_03_0090.htmType A Meetings:Immediately necessary for an otherwise stalled drug development program to proceed. Type A meetings may include: Dispute resolution meetings as described in the Code of Federal Regulations (CFR), and in the Guidance for Industry Formal Dispute Resolution: Appeals Above the Division LevelMeetings to discuss clinical holds in which development is stalled and a new path forward should be discussedSpecial protocol assessment meetings that are requested by sponsors or applicants after receipt of FDA evaluation of protocols under the special protocol assessment proceduresPost-action meetings requested by the sponsor within 3 months after an FDA regulatory action other than an

[markbarker] 01/12/2020 11:04

Nice 500k delayed buy

[csmwssk12hu] 01/12/2020 10:52

They are all paying up for warrants because they are expecting a sharp rise in share price and don’t want to put a downer on a rise, last time I saw this kind of activity was Eurasia mining when all of a sudden every man and his fog started paying for warrants sub 1p, now they are 30p after great news, same here imho dyor

[bbluesky] 01/12/2020 09:09

All the fancy fundraising has killed the share for punters (good for the company of course) in recent times: the moment there is a spark it is quickly drowned out. So, just another "100m" to go at 13.5 then!! Presumably, when this is absorbed we will move quickly to a more reasonable price.

[dandu69] 30/11/2020 13:09

i`ve halved my holding in DNL today to invest in here. Very similar companies, to spread the risk more than anything.

[albert arthur] 30/11/2020 11:55

I'm here holding tight.

[tarny] 30/11/2020 10:04

Hello, Yes waiting for 30p within the next 2 weeks ;o)

[abbynat] 30/11/2020 09:56

hello, is anybody here anymore? there is some blue going on here!

[parc1] 26/11/2020 15:40

Hi LLOL

The advantage this time is from what Avion have learned from the previous data.

Withdrawing patients count as non-responders. Perhaps there is a common factor to filter / partially filter those patients.
Dosage variation
Locations producing high Placebo results.

"This contrasting result in the US compared to the positive result in the Europe cohort, may be due to a number of differing factors between the two cohorts, which requires further investigation".

The differing factors will have been investigated. Avion then put forward $25m funding.

[lord loads of lolly] 26/11/2020 11:15

Hi parc1 - Sure Avion may be onto something. Or they could be barking up the wrong tree. It's a calculated gamble in other words. If Phase 3 trial results fail to find clear water between the drug and a placebo, then the drug isn't be proven to be effective. Not to say it won't be with revised trial terms of course.